TAPUR Study Overview

The primary objective of the Targeted Agent and Profiling Utilization Registry (TAPUR^TM) Study is to describe the anti-tumor activity and toxicity of Food and Drug Administration (FDA)-approved, targeted anti-cancer drugs prescribed for treatment of patients whose tumors have genomic alterations known to be drug targets or predicted sensitivity to a TAPUR Study drug. The TAPUR Study offers a clinical trial opportunity for patients with advanced cancer who have not responded or are no longer responding to standard treatment.

How the TAPUR Study Works

TAPUR Infographic: How it Works

Patient Eligibility

The TAPUR Study is enrolling patients at clinical sites around the country. Review the statements below to determine if your patient may be eligible for the TAPUR Study. For detailed eligibility criteria, refer to criteria listed on www.clinicaltrials.gov; NCT02693535, or contact the TAPUR Study team using the “Contact Us” form below.

Advanced cancer (including solid tumors, multiple myeloma, and B cell non-Hodgkin lymphoma) with a genomic variant identified through a genomic profiling test that can be targeted with a study drug

No longer benefiting from standard treatment, or no standard treatment available

Healthy enough to participate (ECOG Performance Status 0-2)

Must have measurable or evaluable disease

Participating Centers

The TAPUR Study is open and enrolling patients at 113 clinical sites. Most of the clinical sites are part of a larger network, and all questions and/or referrals should be directed to the primary contact at the main operations center.

Find a Center

TAPUR Study News & Updates

View the latest study news, including links to press releases, information on study progress, and timely updates of interim cohort analyses and closures.